Cytoplasmic and nuclear programmed death ligand 1 expression in peritumoral stromal cells in breast cancer: Prognostic and predictive value

  • 0Department of Oncology, Orenburg State Medical University, Orenburg 460021, Orenburgskaya Oblast, Russia.

|

|

Summary

This summary is machine-generated.

Assessing programmed death ligand 1 (PD-L1) expression in breast cancer (BC) stromal cells, specifically the PDCD1 LG1-positive lymphocyte (PDCD1 LG1+ LF) score, alongside lymphovascular invasion (LVI), improves prediction of metastasis to regional lymph nodes (RLNs).

Area Of Science

  • Oncology
  • Immunology
  • Pathology

Background

  • Breast cancer (BC) remains a leading cause of cancer mortality in women.
  • Programmed death ligand 1 (PD-L1) is a key marker in BC progression.
  • Previous studies focused on PD-L1 in tumor cells; its role in stromal cells requires further investigation.

Purpose Of The Study

  • To investigate programmed cell death protein 1 ligand 1 (PDCD1 LG1) expression in BC stromal cells.
  • To determine the relationship between PDCD1 LG1 expression in stromal cells and BC clinicopathological characteristics.

Main Methods

  • Prospective observational study of 148 newly diagnosed BC patients.
  • Immunohistochemical staining for PDCD1 LG1 on tumor samples.
  • Assessment of PDCD1 LG1 expression in lymphocytes, polymorphic cell infiltrates, fibroblastic stroma, and endothelial cells.

Main Results

  • PDCD1 LG1+ lymphocyte (PDCD1 LG1+ LF) score ≥ 3 was more frequent in stages N0 and N3.
  • PDCD1 LG1+ infiltrates and fibroblastic stroma correlated with negative estrogen receptor status, HER2-positive BC, and specific BC subtypes.
  • Regional lymph node (RLN) metastasis risk depends on lymphovascular invasion (LVI) and PDCD1 LG1+ LF score.

Conclusions

  • Combined assessment of PDCD1 LG1+ LF score and LVI enhances prediction accuracy for RLN metastasis in BC patients.
  • This combined approach offers improved prognostic value for BC management.